Colley Clarke appointed CFO of Biosign Technologies

TORONTO, April 25 /CNW/ - Biosign Technologies Inc.(TSXV: BIO) ("Biosign") announces the appointment of Colley Clarke as interim Chief Financial Officer (CFO). Mr. Clarke is known for his financial leadership of TSX Venture Exchange and NASDAQ listed companies in the technology, media and communications industries. He will oversee Biosign's finance, accounting and investor relations functions, while focusing on the company's growth and profitability. Reporting to President and CEO, Dr. Radu Leca, Mr. Clarke will be involved in strategic planning, operations and executive recruiting.

"Colley is an accomplished executive with international experience in finance, capital markets, corporate strategy, operations management, investor relations, legal and human resources," stated Radu Leca. "We are confident that he will help us accomplish our mission of becoming a leader in global health monitoring."

Mr. Clarke has served as CFO of Redknee Solutions Inc. (TSX: RKN), The Descartes Systems Group Inc. (Nasdaq, TSX: DSG), BCE Media, Canadian Satellite Communications Inc. and WPP Group Plc. Mr. Clarke currently serves as the Chairman of the Board and Chair of the Audit Committee for the Edleun Group, Inc. (TSXV: EDU). He is a Chartered Accountant, with an MBA from the Ivey School of Business in London.

Mr. Clarke succeeds Scott Worthington, who has decided to leave the company following the departure of Chief Executive Peter Tassiopoulos last week.

About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit

Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


SOURCE Biosign Technologies Inc.

For further information:

Biosign Contact Information
Radu Leca
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
  Alan S. Roemer, SVP
The Trout Group LLC
Phone: 646 378-2900


Profil de l'entreprise

Biosign Technologies Inc.

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.